Last updated: 11/19/2019 17:30:16

A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age >65 years) with major depression.

GSK study ID
MY-060/BRL-029060/1.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age >65 years) with major depression.
Trial description: A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age >65 years) with major depression.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
1990-01-08
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
A pharmacokinetic dose titration study in adult and elderly depressed patients. Hebenstreit, G. F., Fellerer, K., Zochling, R., Zentz, A., and Dunbar, G. C. Acta Psychiatr Scand Suppl 89; 350(81-4)
Hebenstreit GF et al. A multicenter, double-blind, randomized dose titration study comparing the efficacy and tolerability of oral paroxetine and amitriptyline in geriatric patients with major depression. European Neuropsychopharmacology 1991; 1:440-441(poster presentation)
Medical condition
Depressive Disorder
Product
paroxetine
Collaborators
Not applicable
Study date(s)
August 1988 to August 1990
Type
Interventional
Phase
3

Participation criteria

Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable

Trial location(s)

This study does not involve prospective enrollment of participants.

Study documents

Scientific result summary
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Study complete
Actual primary completion date
1990-01-08
Actual study completion date
1990-01-08

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website
A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age >65 years) with major depression., Trial ID MY-060%2FBRL-029060%2F1. | GSK